NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $2 | $2 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $1 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -98.2% | 542.9% | -76.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -20,672.7% | -185.9% | -2,312.7% | -874.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -20,691.1% | -90.7% | -1,327.3% | -721.7% |
| EPS Diluted | -0.61 | -0.15 | -0.34 | -0.98 |
| % Growth | -306.7% | 55.9% | 65.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |